Dr. Canaani received his MD from The University of Tel Aviv School of Medicine followed by residency in Internal Medicine at The Tel Aviv Medical Center, and laboratory research at the Weizmann Institute of Science. He completed a clinical fellowship in hematology/oncology at the Hospital of the University of Pennsylvania and subsequently served as the director of the Adult Leukemia Program of The Sheba Medical Center. His main area of research has been focused on conducting translational research in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), which aims to delineate molecular correlates that are associated with specific response patterns in leukemia patients receiving conventional chemotherapies and novel targeted therapies. In collaboration with the European Society for Blood and Marrow Transplantation (EBMT), Dr. Canaani made several important contributions to clinical research outlining the clinical outcomes of AML and ALL patients undergoing allogeneic stem cell transplantation. He is an Associate Professor of Medicine (Pending Appointment at Rank) in the Division of Hematology and Medical Oncology at Weill Cornell Medicine caring for patients with blood cancers as part of the NewYork-Presbyterian Medical Group Brooklyn.